Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19815204 | 1.00 | TYMP (0.30) | TYMP | |
| SCHEMBL19825396 | 1.00 | TYMP (0.30) | TYMP | |
| SCHEMBL3033241 | 0.92 | TYMP (0.34) | TYMP | |
| SCHEMBL26534265 | 0.86 | — | — | |
| SCHEMBL23425409 | 0.84 | TYMP (0.35) | TYMP | |
| SCHEMBL19820358 | 0.83 | TYMP (0.39) | TYMP | |
| SCHEMBL21401315 | 0.83 | TYMP (0.39) | TYMP | |
| SCHEMBL19814139 | 0.83 | TYMP (0.39) | TYMP | |
| SCHEMBL23827224 | 0.83 | TYMP (0.34) | TYMP | |
| SCHEMBL23827226 | 0.83 | TYMP (0.34) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363706-A1 | 5`S-LNA nucleotides and oligonucleotides | HOFFMANN-LA ROCHE INC. | 2022-11-17 | — | — | US | claimed |
| US-11390641-B2 | 5′S-LNA nucleotides and oligonucleotides | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | claimed |
| US-20190292213-A1 | 5`S-LNA nucleotides and oligonucleotides | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | US | claimed |
| US-20220363706-A1 | 5`S-LNA nucleotides and oligonucleotides | HOFFMANN-LA ROCHE INC. | 2022-11-17 | — | — | US | disclosed |
| US-11390641-B2 | 5′S-LNA nucleotides and oligonucleotides | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20190292213-A1 | 5`S-LNA nucleotides and oligonucleotides | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-26 | — | — | US | disclosed |
| EP-3491001-A1 | 5'S-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES | Roche Innovation Center Copenhagen A/S (DK) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018019748-A1 | 5'S-LNA NUCLEOTIDES AND OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292213-A1 | 5`S-LNA nucleotides and oligonucleotides | DHFR, NSUN3, NSUN2 | TYMP 21/4885 |
| US-20220363706-A1 | 5`S-LNA nucleotides and oligonucleotides | DHFR, NSUN3, NSUN2 | TYMP 22/4885 |
| US-11390641-B2 | 5′S-LNA nucleotides and oligonucleotides | NSUN3, NSUN2, DHFR | TYMP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.